New combo therapy aims to cut stomach bleeding risk in heart patients
NCT ID NCT07497893
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether adding fexuprazan, a stomach acid reducer, to standard blood thinners can prevent upper gastrointestinal bleeding in people with atrial fibrillation. About 1,000 high-risk participants will be randomly assigned to receive either the combination therapy or blood thinners alone. The main goal is to see if fexuprazan reduces the chance of serious stomach bleeding over one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fexuprazan
What this could lead to
If it works, this could show that adding fexuprazan to blood thinners reduces the risk of serious stomach bleeding in people with atrial fibrillation.
What could go wrong
This trial hasn't started yet, and it's testing a new use for fexuprazan. The expected benefit is based on assumptions, and the results may not show a clear advantage over current care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ewha Womans University Mokdong Hospital
Seoul, 1071, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••